L-Stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease

Neurobiology of Aging

Volumn 31, Issue 6, 2010, Pages 926-936

  Mo, Jiao ^a   Zhang, Hai ^a   Yu, Lei Ping ^a   Sun, Pei Hua ^a   Jin, Guo Zhang ^a   Zhen, Xuechu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

5 HT1A receptor; Dyskinesia; L Stepholidine; Parkinson's disease; Partial agonist

Indexed keywords

BENSERAZIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; MESSENGER RNA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; STEPHOLIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG POTENCY; DYSKINESIA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BERBERINE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DYSKINESIAS; GENE EXPRESSION REGULATION; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RNA, MESSENGER; SEROTONIN AGONISTS; TRANSFECTION; TRITIUM;

EID: 77951974540     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.06.017     Document Type: Article

References (59)

1. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
2. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
3. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
4. 3 receptor function. Nat. Med. 2003, 9:762-767.
5. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 2003, 184:285-294.
6. Blandini F. Adenosine receptors and l-dopa-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach. Exp. Neurol. 2003, 184:556-560.
7. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 2005, 20:919-931.
8. Brotchie J.M., Lee J., Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J. Neural. Transm. 2005, 112:359-391.
9. Cai N. A controlled study on the treatment of tardive dyskinesia using 1-stepholidine. Chin. J. Neurol. Psychiatry 1988, 21(281-283):319.
10. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-dopa-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
11. Cenci M.A., Lee C.S., Bjorklund A. l-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
12. 1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 1989, 9:125-133.
13. 1 dopamine receptors in calf striatum. Biochem. Pharmacol. 1997, 54:227-232.
14. Dong Z.J., Guo X., Chen L.J., Han Y.F., Jin G.Z. Dual actions of (-)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum. Life Sci. 1997, 61:465-472.
15. Ellenbroek B.A., Zhang X.X., Jin G.Z. Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacol. Sin. 2006, 27:1111-1118.
16. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001, 39:288-296.
17. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E. Persistent behavioral sensitization to chronic l-dopa requires A2A adenosine receptors. J. Neurosci. 2002, 22:1054-1062.
18. 1 receptor modulating glutamate NR1a/NR2B receptor function. Acta Pharmacol. Sin. 2007, 28:756-762.
19. 3 dopamine receptors. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S25-29.
20. 3 receptor expression and triggers behavioural sensitisation. Nature 2001, 411:86-89.
21. 3 receptor expression: therapeutic implications in Parkinson's disease. Eur. J. Pharmacol. 2003, 480:89-95.
22. Huang K.X., Sun B.C., Jin G.Z. (-)-Stepholidine: a dopamine receptor antagonist shows agonistic effect on rotational behavior in 6-hydroxydopamine-lesioned rats. Acta Pharmacol. Sin. 1992, 13:17-22.
23. Iravani M.M., Jackson M.J., Kuoppamaki M., Smith L.A., Jenner P. 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 2003, 23:9107-9115.
24. Jerning E., Svantesson G.T., Mohell N. Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. Eur. J. Pharmacol. 1998, 360:219-225.
25. Jiang Y.P., Jin G.Z. Treatment of Parkinson's disease with l-stepholidine. Chin. J. Clin. Neurosci. 2001, 9:424-425.
26. Jin G.Z. (-)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol. Sci. 1987, 8:81-82.
27. Jin G.Z., Huang K.X., Sun B.C. Dual actions of (-)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem. Int. 1992, 20(Suppl.):175S-178S.
28. 2 receptor antagonist actions. Trends Pharmacol. Sci. 2002, 23:4-7.
29. Kaelin-Lang A., Liniger P., Probst A., Lauterburg T., Burgunder J.M. Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J. Neural. Transm. 2000, 107:851-859.
30. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 2000, 162:321-327.
31. Knobelman D.A., Kung H.F., Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J. Pharmacol. Exp. Ther. 2000, 292:1111-1117.
32. Le W. Clinical study on the treatment of dyskinesia by l-stepholidine. Chin. J. Neurol. Psychiatry 1989, 22(335-337):332-381.
33. Lee C.S., Cenci M.A., Schulzer M., Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(Pt. 7):1365-1379.
34. Li R.K., Chen L.J. Treatment of Parkinson's disease with l-stepholidine plus bromocriptine. Chin. J. Integr. Tradit. West. Med. 1999, 19:428-429.
35. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
36. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-dopa-induced dyskinesia. J. Neurochem. 2003, 84:1398-1410.
37. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-dopa-induced dyskinesia. Exp. Neurol. 2005, 194:66-75.
38. Mo Y.Q., Jin X.L., Chen Y.T., Jin G.Z., Shi W.X. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology 2005, 30:261-267.
39. Mo J., Guo Y., Yang Y.S., Shen J.S., Jin G.Z., Zhen X. Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications. Curr. Med. Chem. 2007, 14:2996-3002.
40. Monville C., Torres E.M., Dunnett S.B. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 2005, 68:16-23.
41. Newman-Tancredi A., Wootton R., Strange P.G. High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells. Biochem. J. 1992, 285(Pt. 3):933-938.
42. Nicholson S.L., Brotchie J.M. 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 2002, 3(Suppl.):1-6.
43. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
44. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G. Loss of bidirectional striatal synaptic plasticity in l-dopa-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
45. Quinn N. Drug treatment of Parkinson's disease. Br. Med. J. 1995, 310:575-579.
46. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 2000, 342:1484-1491.
47. 1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol-Chicago. 2001, 58:249-254.
48. Shi W.X., Chen Y., Jin G.Z. Effect of l-stepholidine on rotational behavior in rats. Acta Pharmacol. Sin. 1984, 5:222-225.
49. 2 receptor contributions to l-dopa-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 2005, 81:887-893.
50. Tomiyama M., Kimura T., Maeda T., Tanaka H., Kannari K., Baba M. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with l-dopa. Synapse 2004, 52:218-222.
51. Wang L.H., Liu Q.Z., Zhou C.L. Preliminary study of l-stepholidine in the treatment of schizophrenia. Shandong Arch. Psychiatry 2000, 13:38-40.
52. 3 receptor. Eur. J. Pharmacol. 2000, 407:47-51.
53. Xiao D., Bastia E., Xu Y.H., Benn C.L., Cha J.H., Peterson T.S. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 2006, 26:13548-13555.
54. Xing X.Z., Xie C.G., Wu D.C. A double-blind comparison study of l-stepholidine and clozapine in the treatment of schizophrenia. Shandong Arch. Psychiatry 2002, 15:79-80.
55. Xu S.X., Yu L.P., Han Y.R., Chen Y., Jin G.Z. Effects of tetrahydroprotoberberines on dopamine receptor subtypes in brain. Acta Pharmacol. Sin. 1989, 10:104-110.
56. Yang F.Z., Xiao X.S., Zhu X.M., Jin G.Z. Effects of l-stepholidine on open-field behavior and discrimination learning in mice. Acta Pharmacol. Sin. 1987, 8:390-392.
57. Zhang H., Ma L., Wang F., Chen J., Zhen X. Chronic SKF83959 induced less severe dyskinesia and attenuated l-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 2007, 53:125-133.
58. 2 dopamine receptor supersensitivity in a rat model of Parkinson's disease. Mol. Pharmacol. 2002, 62:1356-1363.
59. 1 agonistic action of (-)-stepholidine in lesioned rats. Biochem. Pharmacol. 1997, 54:233-240.